Home > Insider Trading > Filing (0001365618-10-000004)

Filing Details

Accession Number:: 0001365618-10-000004
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-04-28 13:00:00
Reporting Period:: 2010-04-27

Filing Date:: 2010-04-28
Accepted Time:: 2010-04-28 17:04:40
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1267602	Alimera Sciences Inc	ALIM	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365618	D Anders Hove	C/O Venrock 530 Fifth Ave. 22Nd Floor New York NY 10036		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-04-27	2,243,732	$0.00	2,243,732	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-04-27	934,110	$0.00	3,177,842	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-04-27	465,157	$0.00	3,642,999	No	4	C	Indirect	By Funds
Common Stock	Acquisiton	2010-04-27	306,071	$11.00	3,949,070	No	4	P	Indirect	By Funds

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	C	Indirect	By Funds
No	4	P	Indirect	By Funds

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2010-04-27	2,243,732	$0.00	2,243,732	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2010-04-27	934,110	$0.00	934,110	$0.00
Common Stock	Series C-1 Convertible Preferred Stock	Disposition	2010-04-27	465,157	$0.00	465,157	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2010-04-27	7,500	$0.00	7,500	$11.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
7,500	2020-04-27	No	4	A	Direct

Footnotes

Each share of the Issuer's convertible preferred stock automatically converted into shares of common stock on a one for one basis immediately upon the closing of the Issuer's initial public offering.
The Issuer's convertible preferred stock does not have an expiration date and automatically converted into shares of common stock upon the closing of the Issuer's initial public offering.
The shares, on a post conversion basis, are held as follows: 1,826,398 shares held by Venrock Associates IV, L.P. ("VA4"), 372,460 shares held by Venrock Partners, L.P. ("VP") and 44,874 shares held by Venrock Entrepreneurs Fund IV, L.P. ("VEF4"). Venrock Management IV, LLC ("VM4"), Venrock Partners Management, LLC ("VPM") and VEF Management IV, LLC ("VEFM4") are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The shares, on a post conversion basis, are held as follows: 760,367 shares held by VA4, 155,062 shares held by VP and 18,681 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The shares, on a post conversion basis, are held as follows: 378,639 shares held by VA4, 77,215 shares held by VP and 9,303 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The option shall vest 25% on April 27, 2011, and the remainder of the option shall vest quarterly in equal installments over the subsequent three years, beginning on July 27, 2011.
Dr. Hove is a member of VR Management, LLC (the "Management Company"). Under an agreement between Dr. Hove and the Management Company, Dr. Hove is deemed to hold the reported option for the sole benefit of the Management Company and must exercise the option solely upon the direction of the Management Company, which is entitled to the shares issued upon exercise. The Management Company may be deemed the indirect beneficial owner of the option, and Dr. Hove may be deemed the indirect beneficial owner of the option through his interest in the Management Company. Dr. Hove disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein.
The shares are held as follows: 1,826,398 shares held by VA4, 372,460 shares held by VP and 44,874 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The shares are held as follows: 2,586,765 shares held by VA4, 527,522 shares held by VP and 63,555 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The shares are held as follows: 2,965,404 shares held by VA4, 604,737 shares held by VP and 72,858 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.
The shares are held as follows: 3,214,546 shares held by VA4, 655,545 shares held by VP and 78,979 shares held by VEF4. VM4, VPM and VEFM4 are the sole general partners of VA4, VP and VEF4, respectively. Dr. Hove is a member of VM4, VPM and VEFM4. Dr. Hove expressly disclaims beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of his indirect pecuniary interest therein. VM4, VPM and VEFM4 expressly disclaim beneficial ownership over all shares held by VA4, VP and VEF4, except to the extent of their indirect pecuniary interest therein.